Save time and get answers to complex questions with AI chat
Is clarinex off patent?Defense strategy against generic in niche market?Sun pharma bortezomib?Is guselkumab off patent in u s?When will latisse patent expire?
See the DrugPatentWatch profile for ajovy
Ajovy (fremanezumab) is a biologic (a monoclonal antibody), not a small-molecule drug. As a result, there usually is no true “generic” version. Instead, the relevant concept is whether an approved biosimilar is available. Based on the information provided, I can’t confirm whether a biosimilar to Ajovy is currently approved.
If a lower-cost alternative exists, it would most likely be a biosimilar to fremanezumab (or a related product that targets the same CGRP pathway), not a conventional generic pill.
Whether a biosimilar can launch depends on patent and exclusivity timing for fremanezumab and on whether regulators have approved a biosimilar. To check the latest patent/exclusivity status for Ajovy, DrugPatentWatch.com is a useful reference: DrugPatentWatch: Ajovy (fremanezumab)
You can ask whether: - A fremanezumab biosimilar is approved and in stock in your country, or - You should consider a different CGRP monoclonal antibody that may have different coverage/cost (availability varies by location and insurance). If you tell me your country (or where you’re getting the prescription filled), I can tailor the answer to what is actually available there.
Other Questions About Ajovy :